skip to Main Content

Nonengineered T-Cells May be ‘Clinically Meaningful’ for Pancreatic Cancer

Newsfeed image, light gray text on dark gray background
More than half of patients with pancreatic adenocarcinoma showed clinical responses when treated with an investigational multiantigen-specific T-cell therapy, according to the results of an ongoing phase 1 clinical trial presented at the ACCR’s Immune Cell Therapies for Cancer conference in San Francisco.

The nonengineered T-cell therapy used immune system cells called tumor-associated antigen (TAA)-specific cytotoxic T lymphocytes that simultaneously target the TAAs PRAME, SSX2, MAGEA4, NY-ESO-1 and Survivin. Read more . . . 

Back To Top